Skip to main content
Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALGS ISIN · US01626L2043 LEI · 549300UU2UJIKJYX0S67 US Professional, scientific and technical activities
Open in API
Filings indexed 316 across all filing types
Latest filing 2026-04-21 Regulatory Filings
Country US United States of America
Listing US ALGS

About Aligos Therapeutics, Inc.

https://www.aligos.com/

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for liver and viral diseases. The company leverages expertise in medicinal chemistry and biology to create differentiated, best-in-class drug candidates for conditions with significant unmet medical needs. Its development pipeline features Pevifoscorvir sodium, an oral small molecule capsid assembly modulator (CAM-E) for chronic hepatitis B (CHB), and ALG-055009, an oral small molecule thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH). Aligos aims to develop therapies with enhanced pharmacologic properties suitable for both monotherapy and combination treatment regimens.

Recent filings

Filing Released Lang Actions
8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 16, 2026, reporting the entry into a material definitive agreement (a License Agreement) between Aligos Therapeutics, Inc. and Xiamen Amoytop Biotech Co., Ltd. The content details the terms of the license, payments, rights, and obligations, which is typical for a current report disclosing significant corporate events or agreements. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement of a material contract. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2026-04-21 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-11 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 29, 2026. The content describes the appointment of a new Principal Accounting Officer and the departure of the previous one, which is a change in senior management. There are no financial statements or detailed financial data presented. The document is focused on management changes, specifically the appointment of a new officer. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3641 characters, which is consistent with a typical 8-K management change filing. Hence, the classification is MANG with high confidence.
2026-02-04 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.